

Clinical trials of BID BIAsp 30

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
BID BIAsp 30 vs TID BIAsp 30			
Yang , 2009 n=NA follow-up:	Thrice-daily biphasic insulin aspart 30 versus BID BIAsp 30	Chinese patients with type 2 diabetes inadequately controlled with oral antidiabetic agents	China

More details and results :

- insulin therapy for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q548>

References

Yang, 2009:

Yang WY, Ji QH, Zhu DL, Yang JK, Chen LL, Liu ZM, Yu DM, Yan L, Thrice-daily biphasic insulin aspart 30 may be another therapeutic option for Chinese patients with type 2 diabetes inadequately controlled with oral antidiabetic agents. Chin Med J (Engl) 2009;122:1704-8. [[19719975](#)]